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In the context of head and neck cancer (HNC) adaptive radiation therapy (ART), the two purposes of the study were to compare
the performance of multiple deformable image registration (DIR) methods and to quantify their impact for dose accumulation,
in healthy structures. Fifteen HNC patients had a planning computed tomography (CT0) and weekly CTs during the 7 weeks
of intensity-modulated radiation therapy (IMRT). Ten DIR approaches using different registration methods (demons or B-spline
free form deformation (FFD)), preprocessing, and similarity metrics were tested. Two observers identified 14 landmarks (LM)
on each CT-scan to compute LM registration error. The cumulated doses estimated by each method were compared. The two
most effective DIR methods were the demons and the FFD, with both the mutual information (MI) metric and the filtered
CTs. The corresponding LM registration accuracy (precision) was 2.44mm (1.30mm) and 2.54mm (1.33mm), respectively. The
corresponding LM estimated cumulated dose accuracy (dose precision) was 0.85Gy (0.93Gy) and 0.88Gy (0.95Gy), respectively.
The mean uncertainty (difference between maximal and minimal dose considering all the 10 methods) to estimate the cumulated
mean dose to the parotid gland (PG) was 4.03Gy (SD= 2.27Gy, range: 1.06–8.91 Gy).
1. Introduction
Large anatomical variations can be observed during the seven
weeks of head and neck cancer (HNC) intensity-modulated
radiation therapy (IMRT) treatment course, such as weight
loss [1, 2], primary tumor shrinking [1], parotid gland (PG)
volume reduction [3], and reduction of the neck diameter
[4, 5]. Consequently, the actual delivered dose does not
correspond to the optimized pretreatment planned dose,
with a risk of overdose of the organ at risk (OAR), in
particular the PG [6, 7]. Indeed, if IMRT has been shown,
compared to non-IMRT techniques, to dramatically decrease
the dose in the PG and therefore the risk of xerostomia [8–
10], the benefits of IMRT are however likely reduced by these
anatomical variations [6, 7]. Setup errors are relatively easily
corrected by a simple rigid registration based on the bony
structures. Volume and shape variations can be compensated
by replanning, therefore implying to perform new computed
tomography (CT) scans during the course of treatment, since
the CBCT cannot be yet straightly used for replanning. This
recent adaptive radiotherapy (ART) strategy appears however
complex, in particular to decide when and how many times
to replan during the treatment course [11, 12]. In this context,
a key step is the capability to monitor the cumulated dose
received by the deformed OARs, fraction after fraction, then
to compare this dose with the planned dose, and finally
to decide whether or not to replan within a dose-guided
adaptive radiotherapy strategy [13, 14].
Deformable image registration (DIR) is a keystone of
the dose accumulation process (Figure 1). Different DIR
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Figure 1: Full cumulated dose scheme in 5 steps. CT: computed tomography (scan).
methods have been proposed to register HNC X-Ray CT
images [15, 16]. Particularly, the two most popular DIR
methods, demons’ and the free form deformation (FFD)
methods have been considered. Demons’ method computes
a dense deformation field, which is smoothed to provide a
regular field [17]. The FFD approach deforms a grid of a
limited number of control points, whose displacements are
interpolated using generally a B-spline function to provide a
dense field [18].Thus, thesemotion regularization approaches
are very different. Moreover, other important choices have
to be made when using DIR. The similarity metric, used to
quantify the matching quality between voxels, is a decisive
option and is highly dependent on the considered images.
The mean squared error (MSE) is the most classical metric
when dealing with monomodal images, and the mutual
information (MI) when registering images with different
intensity ranges. In the case of HNCCTs, if theMSE seems to
be a natural choice, theMI could be useful when the injection
of a contrast agent modifies some tissues’ intensities in only a
subset of the images set. Some preprocessing steps may also
be applied to the images before their registration. Indeed, the
most challenging task of DIR in the considered application
is to estimate the deformation of soft tissues showing a poor
contrast. Using some filters to enhance these tissues or even
using delineations to guide the registration may be helpful to
improve the results.
If the use of DIR appears useful for contour propagation
[19, 20], its use to cumulate the dose is a lotmore controverted
[21–24] and is therefore not yet validated in a clinical practice.
Indeed, one of the key issues is the evaluation of the per-
formance of the DIR methods. Volume-based criterion (i.e.,
dice similarity coefficient (DSC)) can be used [15], providing
however no information regarding the registration’s anatom-
ical “point to point” correspondence precision. Landmarks
(LMs) manually placed by two observers allow to quantify
the local accuracy and precision of DIR, while including the
intraobserver error [25].
In the context of IMRT for locally advanced HNC, based
on weekly CTs in a series of 15 patients, the objectives of this
study were to quantify
(i) the geometrical local accuracy and precision of differ-
ent DIR methods, including images with or without
preprocessing and different similarity metrics;
(ii) the dosimetric impact of using these different meth-
ods for dose accumulation in the OARs, in particular
the PG.
2. Materials and Methods
2.1. Patients and Tumors. The study enrolled a total of fifteen
patients with a mean age of 65 years (ranging from 50 to
87 years). All tumors were locally advanced head and neck
carcinoma (Stage III or IV, AJCC 7th ed), thirteen of them
were located in the oropharynx, one in the larynx and one in
the hypopharynx. The mean PG volume was 25.3 cc (ranging
from 16.6 cc to 52.1 cc, standard deviation (SD) = 8.1 cc).
2.2. Treatment and Planning. All patients underwent IMRT
delivering a total dose of 70Gy (2Gy/fraction/day, 35 frac-
tions), with a simultaneous integrated boost technique [26]
and concomitant chemotherapy. Planning CTs (CT0) with
intravenous contrast agents were acquired with 2mm slice
thickness, from the vertex to the carina. A thermoplastic
head and shoulder mask with five fixation points was used.
PET-CT and MRI coregistration was used for tumor delin-
eation. Three target volumes were generated. Gross tumor
volume (GTV) corresponded to the primary tumor along
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Figure 2: Treatment and workflow study scheme. DIR: deformable image registration, FFD: free form deformation, CT: computed tomo-
graphy (scan), and RT: radiotherapy.
with involved lymph nodes. Clinical target volume 70Gy
(CTV
70
) was equal to GTV plus a 5mm 3D margin, which
was adjusted to exclude air cavities and bone mass without
evidence of tumor invasion. CTV
63
corresponded to the
area at high-risk of microscopic spread, while CTV
56
corre-
sponded to the prophylactic irradiation area. GTV, CTV
63
,
CTV
56,
and all organs at risk were manually delineated on
each CT slice. Adding a 5mm 3D margin around the CTVs
generated the PTVs. PTV expansion was limited to 3mm
from the skin surface in order to avoid part of the build-
up region and to limit skin toxicity [27]. All IMRT plans
were generated using Pinnacle V9.2. Seven coplanar 6-MV
photon beams were employed with a step and shoot IMRT
technique. The prescribed dose was 70Gy to PTV
70
, 63Gy
to PTV
63,
and 56Gy to PTV
56
. The collapsed cone convolu-
tion/superposition algorithm was used for dose calculation.
The maximum dose within the PTV was 110% (D2%). The
minimum PTV volume covered by the 95% isodose line was
95%. Dose constraints were set according to the GORTEC
recommendations [28]: a mean dose (𝐷mean) < 30Gy and a
median dose < 26Gy for contralateral PGs.
Patients were treated as planned on CT0 and no changes
were applied to dose distribution during treatment. During
the treatment course, weekly in-room stereoscopic imaging
corrected set-up errors > 5mm. All patients signed an
informed consent form.
2.3. Per-Treatment Imaging and Volume Variations. During
the treatment, each patient underwent six weekly CTs (CT1
to CT6) (Figure 2) according to the same modalities as CT0,
except for the intravenous contrast agents (not systematically
used, particularly in case of cisplatin based chemotherapy).
For each patient, the anatomical structures were manually
segmented on each weekly CT by the same radiation oncol-
ogist. In case of complete response, initial macroscopically
involved areas were still included in the CTV
70
, which was
adjusted to exclude any air cavities and bone mass without
evidence of initial tumor invasion.
A total of 102 CT scan have been used in the study, 15
planning CTs and 87 weekly CTs. Figure 3 represents the
differences between the DVH from each weekly CT scan
and from the planning CT (CT0), for the parotid glands, the
spinal cord, the brain stem, and the CTV
70
. The dose at each
fraction is normalized to the total dose (70Gy). The 75%,
50%, and 25% interquantile ranges are represented by colored
ribbons.
From CT0 to CT6, the PG volumes decreased by a mean
value of 28.3% (ranging from 0.0 to 63.4%, SD = 18%),
corresponding to an average decrease of 1.1 cc/week (ranging
from 0.0 to 2.2 cc/week). The CTV
70
decreased by a mean
value of 31% (ranging from 73% to −13%, SD = 28%). The
thickness of the neck decreased for 78% of the patients by a
mean value of 7.9mm (ranging from 0.1 to 26.6mm, SD =
6.2mm).
2.4. Cumulated Dose Estimation. Dose accumulation is
defined by the addition of the dose distributions at different
fractions (in this case from weekly CTs) reported to the plan-
ning CT, by applying to the dose distribution at the fraction,
thanks to elastic registration, the anatomical transformation
from the fraction anatomy to the planning anatomy.The dose
accumulation process relied on four steps, as illustrated in
Figure 1. Firstly, for eachweeklyCT, the anatomical variations
with respect to the planning CT were estimated using DIR
(step 1). The actual weekly dose distribution (step 2) was
estimated by calculating the dose distribution on the weekly
CT, using the treatment parameters and the CT0 isocenter.
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Figure 3: Representation of the DVH differences between the DVH calculated from the weekly CT and the DVH from the planning CT for
(a) the parotid glands, (b) the brain stem, (c) the spinal cord, and (d) the CTV
70
. DVH: dose-volume histogram and CTV
70
: clinical target
volume receiving 70Gy. For each subfigure the dashed lines represent the maximum and the minimumDVH difference values; the black line
represents the mean DVH difference. Each color represents the 75%, 50%, and 25% interquantile range of the data.
The deformation field resulting from DIR was then applied
to the corresponding weekly dose distribution to report it
to the planning CT (step 3). Finally, all the propagated
dose distributions corresponding to all weekly CTs were
summed to compute the cumulated dose (step 4). To select
the appropriate DIR method, some choices had to be made,
especially (Figure 2): (i) the registered images (i.e., with
or without preprocessing); (ii) the DIR approach; (iii) the
considered metric. In this study, a total of 10 combinations
of these criteria were evaluated.
2.4.1. Registered Images. To register each weekly CT to the
planning CT, both original images (without any preprocess-
ing) and images resulting from two preprocessing methods
(sigmoid filtering and delineationmapping) were considered.
Both planning CT and weekly CT images were prepro-
cessed with a sigmoid filter to enhance soft tissues of the
images. Sigmoid filter allowed increasing intensity values
between an arbitrary intensity range and decreasing outside
that defined intensity range:
𝐼
󸀠
= (Max−Min) ∗ 1
1 + 𝑒((𝐼−𝛽)/𝛼)
+Min, (1)
where 𝐼󸀠 represent the intensity 𝐼 transformed in the intensity
value window [Min; Max]. The sigmoid parameters 𝛼 and
𝛽 define, respectively, the width of the input intensity range
and the intensity around which the range is centered. The
value of 𝛼 was 100 Hounsfield units (HU) and 𝛽 was 0HU,
corresponding to the intensity range of soft tissues. The Min
and Max intensity values were, respectively, −1024HU and
2976HU.
In order to focus the registration process on the consid-
ered organs, delineationmaps were also generated, represent-
ing the main delineations (skin, left, and right parotid glands,
spinal cord, and brain stem) with homogeneous intensities.
The assigned intensity values were (1) for the skin, (2) for the
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right parotid, (3) for the left parotid, (4) for the brain stem,
and (5) for the spinal cord.
2.4.2. Deformable Image Registration Methods. Two DIR
methods have been evaluated: demons’ method and the free
form deformations (FFD).
Demons’ algorithm [17] is a nonparametric method
which iteratively estimates a dense deformation field (i.e.,
defined on each voxel) between two images. At each iter-
ation, the deformation field is updated by computing local
forces using the intensity gradient and the difference of the
intensities of the two images. Then, the deformation field is
smoothed using a Gaussian filter (𝜎 = 1 or 𝜎 = 2.5). A multi-
resolution process, including three levels, was used.
The FFD registration method is a parametric registration
method defining a deformation field by an underlying mesh
of control points. The control points are iteratively displaced
according to the considered metric. The dense deformation
field is obtained by a B-spline interpolation [18]. A multires-
olution process, including three levels, was used. At each
iteration, the adaptive stochastic gradient descent (ASGD)
[29] was used to optimize the control point displacements
defined by
𝑥
𝑘+1
= 𝑥
𝑘
− 𝛼
𝑘
∇𝑓 (𝑥
𝑘
) , (2)
where 𝛼
𝑘
represents the step size on 𝑓 along the negative
gradient direction.
The good definition of the gain 𝛼
𝑘
for the convergence of
the ASGD is defined by
𝑎
𝑘
=
𝑎
(𝐾 + 𝐴)
𝛼
, (3)
with 𝑎 = 104, 𝐴 = 51.0, and 𝛼 = 0.602 for head and neck
registration. The resolution of the grid was chosen at 30mm,
20mm, and 10mm and then 5mm for the last resolution.
2.4.3. Metrics for DIR. Two metrics were considered in the
DIR process: the mean squared error (MSE) and the mutual
information (MI).
The mean squared error is defined by
MSE (𝐴, 𝐵) = 1
𝑁
∗
𝑁
∑
𝑖=1
(𝐴
𝑖
− 𝐵
𝑖
)
2
, (4)
where 𝐴
𝑖
and 𝐵
𝑖
are the intensity of the 𝑖th pixel of the 𝐴
and 𝐵 images and 𝑁 is the number of considered pixels.
This metric was used in conjunction with the three types
of images (original images, original images filtered by the
sigmoid filter, and delineationmaps) and the two registration
methods (demons and FFD).
The mutual information is defined by
MI (𝐴
𝑖
, 𝐵
𝑗
) = 𝐻 (𝐴
𝑖
) + 𝐻 (𝐵
𝑗
) − 𝐻(𝐴
𝑖
, 𝐵
𝑗
) , (5)
where 𝐻(𝐴
𝑖
) and 𝐻(𝐵
𝑗
) are the marginal probability distri-
bution functions of the intensities 𝐴
𝑖
and 𝐵
𝑗
and 𝐻(𝐴
𝑖
, 𝐵
𝑗
)
their joint probability distribution function. This metric was
used in conjunction with the original images and the original
images filtered by the sigmoid filter and the two registration
methods (demons and FFD).
For demons’ method, the MSE-based implementation
was the one from ITK [30], while the MI-based implemen-
tation was an in-house method [31].
For the FFDmethod, the implementation provided by the
ElastiX library [32] was used.
Before the DIR step, all the weekly CT images were
rigidly registered to the planning CT using a transformation
defined by six parameters (the three translations and the
three rotations). MSE was used with the descent gradient
optimizer. This rigid registration was also included in the
analysis, together with the different DIR methods.
Table 1 shows a total of 10 final DIR combinations or
methods, each of them including one of the 2 image pre-
processing methods (or no preprocessing), one of the 2 DIR
methods, and one of the 2 metrics.
2.4.4. Contour and Dose Distribution Propagation. The
weekly dose distributions were propagated, using the 10 DIR
and rigid registration methods, from the weekly CTs to the
planning CT, with trilinear interpolation (Figure 1, step 3).
For the evaluation, the contours obtained on the weekly CTs
were also propagated.
2.5. Evaluation of DIR Geometric Performance. TheDIR per-
formance was evaluated using both volume-based criterion,
that is, Dice similarity coefficient and locally by computing
LM registration errors.
2.5.1. Dice Similarity Coefficient (DSC). The Sorensen-Dice is
a similarity coefficient computed between two regions [33].
Its formula is
DICE = 2 ∗ 𝐶
𝐴 + 𝐵
=
2 ∗ |𝐴 ∩ 𝐵|
|𝐴| + |𝐵|
, (6)
where 𝐴 and 𝐵 represent the two regions. 𝐶 represents the
number of shared voxels between the regions. Computed
between the planning delineation of one organ and a weekly
delineation propagated thanks to the deformation field, this
coefficient expresses the overlap between the two regions:
between zero (no overlap) and one (perfect overlap). The
Dice similarity coefficient was computed for the following
structures: the left and right PGs, the mandible, the spinal
cord, the thyroid, the larynx, the brain stem, and the brain.
2.5.2. Landmark Registration Error. Fourteen landmarks
(LM) were defined, as described in Table 4: inside the left and
right PGs, the posterior part of the intervertebral disk C2-
C3, the superior and left part of the sternum (near the left
sternoclavicula joint), the left and right carotid bifurcation,
the left and right lesser cornu of the hyoid bone, the superior
thyroid notch (part of the thyroid cartilage), the lower part
of the mandible, the vallecula, the lower part of the palatine
uvula, the philtrum, and the odontoid. LMs were defined by
a first radiation oncologist expert on the planning CT. The
same expert observer and a second expert observer defined
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afterwards the position of the LMson theweeklyCTs, in order
to assess the interobserver variability.
The 14 LMs on CT0 were propagated to the six weekly
CTs of each patient, for each of the 10 DIRmethods and using
the MSE rigid registration method for comparison. For each
LM and for each weekly CT, the LM registration error of the
differentDIRmethodswas evaluated by computing the three-
dimensional Euclidean distance between the positions of the
LM as assessed by the first expert and as propagated by the
deformation field estimated by DIR.
The DIR method performance was evaluated by the
accuracy and precision parameters. The accuracy is defined
by the average LM registration error, and the precision
is defined by the average standard deviation of the LM
registration error.
2.6. Dosimetric Impact of the DIR Methods for Dose Accumu-
lation. To evaluate the dosimetric impact of the DIR errors,
the reference cumulated dose was computed for each LM, by
summing the weekly doses corresponding to the LM posi-
tions on the weekly CTs defined by the first expert. The same
process was applied to cumulate the dose in the LM positions
as assessed by the DIR methods, the rigid registration and by
the second observer (interobserver variability). The cumu-
lated dose errors were then calculated and defined by the
differences between the LM reference cumulated dose (from
the first expert) and each of the estimated LM cumulated
doses (from theDIR, from the rigid registrationmethods and
from the second expert). The planned dose corresponding
to each LM has been also given for comparison (Figure 1,
step 5). Such as for the LM registration error, the cumulated
dose, estimated by each method and by the second observer,
was evaluated by the accuracy and precision. The cumulated
dose accuracy was calculated by the average of the difference
between the reference cumulated dose (defined by the first
expert for each LM) and the cumulated dose estimated by
the different methods or the second observer. The cumulated
dose precisionwas calculated by the standard deviation of the
same difference.
The cumulated mean PG dose (considering the whole
PG volume), clinically relevant since being highly correlated
with the risk of xerostomia [34], was also computed for each
DIR method, and finally also compared to the planned dose
(Figure 1, step 5). Three PGs were excluded from the analysis
since being included in the CTV
70
and consequently not
spared at the planning.
2.7. Statistical Analysis. The DIR methods evaluation was
based on the DSC for the contour propagation and on
the LM registration errors for the voxel-to-voxel precision.
The interobserver variability was quantified by considering
the LM distance between the first and the second expert
observers. An analysis of variance (ANOVA) was carried out
to assess the impact of each of the DIR methods (Table 1)
on the DSC and LM error. Using ANOVA contrasts, all
methods were tested against all methods. For all pairs (X,
Y) of methods, the tested null hypothesis was H0: the mean
error provided by “method X” is lower than the mean error
provided by “method Y”, against the alternative hypothesis
Ha: mean errors of “method X” and “Y” are equal. This
procedure allows the identification of the DIR methods (or a
subgroup of DIRmethods) that leads to the lower mean error
and also allows for intrapatient variability to be controlled.
Statistical analysis was carried out using the R language
and environment for statistical computing.
3. Results
3.1. Deformable Image Registration Geometric Performance
3.1.1. Dice Similarity Coefficient forDIRGeometric Evaluation.
Figure 4 shows the DSC distribution corresponding to each
of the 10 DIR methods and the rigid registration, for all the
structures (Figure 4(a)) and the PGs only (Figure 4(b)).
(i) Considering all the anatomical structures, the three
methods corresponding to the maximum DSC were
the “demons with MSE on delineation maps,” the
“FFD with MI on filtered CTs” and the “demons
with MI on filtered CTs.” The corresponding median
(standard deviation) DSC values were 0.91 (0.16), 0.83
(0.09), and 0.82 (0.09), respectively. The “FFD with
MI on filtered CTs” DSC values were higher than the
DSC values of all other methods (P ≤ 0.01), except
the “demons withMSE on delineationmaps”method.
The “demons with MI on filtered CTs” DSC was
superior to all DSC methods with MSE on original
CTs (P ≤ 0.05), except the “demons with MSE on
delineation maps” method.
(ii) Considering only the PGs, the “demons with MSE on
delineation maps” DSC values were higher than the
DSC values of all othermethods (𝑃 < 0.01).The “FFD
with MI on filtered CTs” DSC values were superior to
the DSC values of 7 among the 9 other DIR methods
(𝑃 < 0.05).
Regardless of the anatomical structures, the DSC of all
DIRmethodswas superior to theDSCof the rigid registration
(𝑃 < 0.01).
3.1.2. Landmark Registration Error. Table 2 shows the mean
Euclidean distance between the positions of the landmark
(LM) assessed by the first expert (reference) and the positions
propagated by the 10 considered DIR methods, the rigid reg-
istration and the second expert, for each LM.The table orders
the methods, from the minimum to the maximum distance.
The minimum mean error (2.44mm) corresponds to the
“FFD with MI on filtered CTs” method, while the maximum
error (5.16mm) corresponds to the rigid registration.
The interobserver distance (between the positions of
the LM assessed by the two expert observers) results to
an average error representative of the accuracy (average
standard deviation representative of the precision) of 2.01mm
(1.29mm).
The two most effective DIR methods were the demons
and the FFD, with both the mutual information (MI) metric
and the filtered CTs as detailed below.
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Figure 4: Boxplot of dice similarity coefficient by registrationmethods for (a) all the structures and (b) the parotid glands. DSC: dice similarity
coefficient, FFD: free formdeformation,MSE:mean squared error,MI:mutual information, andCT: computed tomography (scan).The limits
of each box represent the 25th and 75th percentiles, the whisker represents the min and the max value, and the red line represents the median
(50% of the total values). Each boxplot is represented without the outliers.
(i) Considering all the LMs, the corresponding accuracy
(and precision) were 2.44mm (and 1.30mm) and
2.54mm (and 1.33mm), for each method, respec-
tively. The minimal errors were 1.18mm and 1.13mm
for the odontoid LM, respectively.Themaximal errors
were 5.35mm and 4.58mm for the right carotid
bifurcation LM, respectively. Considering bone LMs
only, accuracy (and precision) were 2.13mm (and
0.99mm) and 2.15mm (and 1.16mm), respectively.
Considering soft tissue LMs only, they were 2.66mm
(and 1.60mm) and 2.88mm (and 1.49mm), respec-
tively. The “FFD with MI on filtered CTs” and the
“demons withMI on filtered CTs” errors were inferior
to 7 among the 9 other DIRmethod errors (𝑃 < 0.05).
(ii) Considering only the PG LMs, the “FFD with MI on
filtered CTs” and the “demons with MI on filtered
10 BioMed Research International
CTs” errors were inferior to 7 among the 9 other DIR
method errors (𝑃 < 0.03).
No method errors were statistically inferior to the inter-
observer variability error considering all LMs and the PG
LMs.
3.1.3. Impact of the Choice of the DIR Method on Dose Accu-
mulation. Table 3 shows the cumulative dose error for each
LM and for each method. The table shows also the planned
dose at each LM and also the reference difference between
planned and cumulated doses (from the first observer). The
two last columns represent the accuracy and the precision of
the methods defined by the average and the average standard
deviation of the cumulated dose differences.
The median (SD) planned dose was 54.18Gy (21.02Gy)
for all LMs, 43.20Gy (6.17 Gy) for the C2-C3 LMs, and
48.18Gy (18.20Gy) for the PG LMs.
(i) Considering all the LMs, the methods corresponding
to the lowest cumulated dose errors were the “FFD
with MI on filtered CTs” and the “demons with
MI on filtered CTs,” with corresponding accuracy
(and precision) of: 0.85Gy (and 0.93Gy) and 0.88Gy
(and 0.95Gy), respectively. The minimal errors were
0.36Gy for the odontoid LM and 0.33Gy for the
sternum LM, for both methods. The maximal errors
were 2.63Gy and 2.74Gy for the right PG LM, for
each of the method, respectively. Considering bone
LMs only, accuracy (and precision) were 0.50Gy (and
0.49Gy), and 0.49Gy (and 0.48Gy) for each of the
method, respectively. Considering soft tissue LMs
only, theywere 1.20Gy (and 1.38Gy), and 1.27Gy (and
1.41 Gy), respectively. The “FFD with MI on filtered
CTs” errors were inferior to the errors of 6 among the
9 remaining DIR methods (𝑃 < 0.03).
(ii) Considering the PG LMs only, the “FFD with MI on
filtered CTs” and “demons with MI on filtered CTs”
errors were inferior to the “demons with MSE on
delineation maps” errors (P ≤ 0.03).
For all the LMs, all method errors except the “demons
with MSE on delineation maps” were statistically inferior to
the rigid registration errors (𝑃 < 0.01).
Considering all the LMs or only the PG LMs, no method
performs better than the second observer.
Figure 5 represents the estimated cumulated mean dose
in the PGs by each method (with a star showing the result
using the “FFD with MI on filtered CTs” method). The
median (SD) mean planned dose for the PGs was 30.22Gy
(7.76Gy).Themedian (SD)mean cumulated dose for the PGs
was 32.62Gy (9.19Gy) by using the “FFD with MI on filtered
CTs” method.
The mean uncertainty (difference between maximal and
minimal estimated cumulated doses considering all the
methods) to estimate the cumulated mean PG dose was
4.03Gy (SD = 2.27Gy, range: 1.06–8.91 Gy). Using the “FFD
with MI on filtered CTs” method to calculate the cumulated
mean PG dose, 66% of the PGs presented an increase of the
mean dose of 3.38Gy (SD = 2.82Gy, range: 0.38–11.69Gy),
and 33% of the PGs presented a decrease of the mean of
1.52Gy (SD = 1.08Gy, range: 0.06–3.22Gy), compared to the
mean planning dose.
Figure 6 represents the DVHs of the planned dose and
of the cumulated dose estimated by all the DIR methods for
one patient (parotid gland number 1 of Figure 5). The blue
line represents the DVH of the “FFD with MI on filtered
CTs” method that has an overall average accuracy (precision)
of 0.68mm (0.75mm) and an average DSC of 0.79 for the
parotid glands. The red line represents the DVH of the
“demon with MSE on delineation maps” method that has
an overall average accuracy (precision) of 1.89mm (2.14mm)
and an average DSC of 0.92 for the parotid glands.
4. Discussion
The goal of our study was to compare different registration
methods with regard to their ability to monitor the accu-
mulated dose in HNC radiotherapy, mainly in deformable
anatomical structures and using CT-scans. Evaluating 10
DIR methods with 14 landmarks, we found that the two
most accurate methods were the demons and the FFD, both
combined with the mutual information metric and filtered
CTs.Their estimated registration accuracy and precisionwere
2.44mm and 1.30mm, respectively, with an improvement
on bony structure against soft tissues up to 0.87mm. The
corresponding LM estimated cumulated dose accuracy and
precision ranged from 0.50 to 0.95Gy. Those corresponding
errors were significantly inferior to the rigid registration
errors by a difference of accuracy andprecision for all the LMs
of 2.72mm and 1.22mm, respectively, with a similar impact
of 1.34Gy and 1.67Gy on the estimated cumulated dose.
Our observed volume diminutions from the beginning to
the end of treatment were 28% for the PGs and 31% for the
CTV
70
, in concordance with the literature reporting values
of 15% to 28% for the PGs, 69% for the GTV, and 8% to
51% for the CTV [1, 3, 11, 12, 19, 35]. The dosimetric impact
of such anatomical variations is particularly important for
organs located close orwithin high dose gradients, such as the
PGs, whose overirradiation leads to xerostomia decreasing
strongly the patient quality of life [6, 7]. In this context, the
ability of dose monitoring by cumulating the dose, fraction
after fraction, is an important step for the implementation
of the dose-guided ART strategy. Indeed, the replanning
decision should be optimally taken by considering the dose
actually delivered to the tissues from the beginning of the
treatment, and by comparing this cumulated dose with the
planned dose. The quantification of the accuracy of the
DIR methods to cumulate the dose in deformable structures
appears therefore particularly crucial to choose the most
appropriate one and make consequently the whole ART
approach clinically feasible.
Weekly CT-scans were used in our study since CBCTs
cannot be considered for an accurate dose calculation, both
at the fraction and for replanning. Moreover, performed just
before or after the fraction, the CTs provide a representative
anatomy of the irradiated patients with a small intrafraction
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Table 4: List of all the 14 landmarks used for the study.
14
1
9
13
10
2
4
11
7
12
5
8
3
6
Landmark
index Tissue landmark Description
1
Bone
The odontoid
2 The lower part of themandible
3
The superior thyroid notch
(part of the thyroid
cartilage)
4-5
The right (4) and left (5)
lesser cornu of the hyoid
bone
6
The superior and left part
of the sternum (near the
left sternoclavicular joint)
7 The posterior part of theintervertebral disk (C2-C3)
8
Soft
The vallecula
9 The philtrum
10 The lower part of thepalatine uvula
11-12 The right (11) and left (12)carotid bifurcation
13-14 The right (13) and left (14)parotid gland (PG)
A total of 7 bony landmarks and 7 soft tissue landmarks have been defined.
anatomical variation. All the planning CTs were however
acquired with a contrast agent injection, while the weekly
CTs were mostly acquired without injection due to the renal
toxicity risk of the cisplatinum, concomitantly given with
the radiotherapy. This makes the registration particularly
challenging since some tissues such as the vessels and the PGs
present therefore different intensity values in the registered
images.
We evaluated the two most popular registration
approaches, demons, and FFD methods, combined with two
metrics and two kinds of preprocessing methods.We showed
that, more than the used DIR approach (demons or FFD),
the considered preprocessing and metric have a significant
impact on the results. As expected, the incorporation of
the delineation maps with demons’ method enables to
increase the DSC, especially for the organs used in the
delineation maps (e.g., PGs). Using the delineation maps
with the FFD approach is not really efficient, since it uses
a grid of control points, which may not lie on the organs
boundaries, that is, the salient information. Our results can
be compared with the study of Castadot et al., analyzing
12 voxel-based DIR strategies with a dataset of 5 HNC
patients imaged with CT before and once during RT [15].
Considering the DSC, the best three strategies were the
demons’ algorithm implemented in multiresolution, the
multiresolution demons combined with level-set, and a
denoising filter and the multiresolution demons combined
a denoising filter. Our DSC values (0.83) are comparable
or slightly inferior using our best method without using
delineations (“FFD with MI on filtered CTs” method),
compared to the 0.86 value obtained by the “demons MSE”
method in the Castadot study [15]. Our study comprised
however more patients and more images per patient, and
all the images were contrast-enhanced in Castadot study.
The DSC, as other region-based criteria (e.g., Jaccard index
or Hausdorff distance), is useful to globally evaluate the
overlap between regions and thus, to evaluate DIR when it is
used for delineation propagation. However, for a local dose
accumulation purpose, an evaluation of the local point to
point matching is needed. Indeed, the method performance
is different when considering a local matching evaluation
provided by the LM registration errors. Our two best DIR
methods are the FFD and the demons, with both MI and
sigmoid filter. Thus, even if the considered images are
monomodal, the intensity differences caused by the contrast
agent injection are better taken into account by the MI
metric. The incorporation of the sigma-filter enables also to
improve the results by enhancing the soft tissues contrast
relatively to the other tissues which naturally present a very
high contrast (especially bones and air). The mean distance
LM registration error was 2.44mm for the “FFD with MI on
filtered CTs” method. It has to be compared to the second
observer mean error which was 2.01mm, showing a high
interobserver variability. Moreover, considering the spatial
resolution of the considered images (mean resolution of
planning CTs: 1.10 × 1.10 × 2.4mm3), this mean error
corresponds to 0.70 times the slice thickness. It should also
be noticed that all the LMs do not present equivalent errors,
showing that some organs are easier to register than some
others. These facilities could be related to the volume of the
organs, where it could be hard to overlap small organ and
preserve the point to point accuracy. The LMs located on
bony structures globally present lower registration errors
than those located on soft tissues, especially on the carotids’
bifurcations (3.85mm for the “FFD with MI on filtered CTs”
method).
When considering the dose accumulation errors, the
methods ranking remains the same, with the best results pro-
vided by consideringMI and sigmoid filtering. It is important
to notice that the geometrical uncertainties may have very
different impact on the cumulated dose errors, depending
on the value of the dose gradient on the considered area: a
high geometrical error located in an areawith a homogeneous
dose distribution has a small impact, while even a small
geometrical error may lead to high cumulated errors if it is
close to a high dose gradient. For example, the “FFD with
MI on filtered CTs” method, providing a mean geometrical
error of 3.85mm and 2.64mm for the carotid bifurcations
and PGs, respectively, results in a mean cumulated dose
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error of 0.69Gy and 2.52Gy, respectively. It shows that, when
considering local dose accumulation, the results should be
considered very carefully, especially for regions with a low
contrast and localized close to high dose gradients such as the
PG. However, the uncertainties resulting from DIR are lower
than the difference between the planned and the delivered
doses at the position of the LMs, showing that DIR could
be useful to detect over- or underirradiation. This is notably
true when considering dose descriptors, such as the mean
dose delivered to the PGs. The DIR methods enable to detect
potential deviations from the planned dose. As shown in
Figures 5 and 6, even considering the uncertainties carried by
the different registrationmethods, it is possible to confidently
identify the globally under- and overirradiated PGs, the
mean uncertainty (difference between maximal and minimal
estimated cumulated dose considering all themethods) being
4.03Gy.
Using the “FFD with MI on filtered CTs” method to
cumulate the mean dose in the PGs and in comparison
with the planning dose, 67% of the PGs were found to be
overirradiated to ameandose of 3.4Gy (up to+11.7 Gy for one
patient), justifying particularly the use of ART in themajority
of locally advanced HNC. On the other hand, surprisingly,
33% of the PGs presented a decrease of the mean PG dose of
1.52Gy (up to −3.2 Gy for one patient).
Figure 3 shows the impact of the anatomical variations on
the dose distribution at the fraction (normalized to 70Gy).
The DVH differences for the CTV are very limited since the
CTV is well treated both at the initial planning and during
the treatment due to the tumor shrinking and to the CTV-
to-PTV margins. On the other hand, for the parotid glands,
the DVH differences along the DVH are ±10% for 75% of the
fractions. For the spinal cord and the brain stem, the DVH
differences are inferior to the parotid gland and below 45Gy
except for one patient who had large anatomical and position
variations.
Such variations in the difference between the planned and
the delivered PG doses justify the development of tools to tar-
get the right patients benefiting the most of the ART strategy.
These tools can be based on a cumulative dose estimation
or more simply, likely on the identification of anatomical
markers ideally on the CBCTs, and early enough in the
course of treatment to propose one or several replanning.
Such markers could be the neck diameter, whose diminution
increases the risk of overirradiation [4, 5].
One limitation of this work is to consider the manual
expert observer as the reference. As shown by the second
observer results, the interobserver variability is high, espe-
cially on low contrast regions. Previous studies proposed the
use of finite-element numerical phantoms [31, 36] in order to
generate automatically organ deformation with known point
to point anatomical correspondence. However, generating
phantomswith realistic deformations is particularly challeng-
ing, especially for theHNC localization, which contains small
structures and presents complex anatomical deformations
such as melting of the tumor and PG deformation. Another
method for DIR evaluation is to replace the expert observer
by an automated process to identify salient points in the
registered images to compute landmark registration errors,
as published by Paganelli et al. [37], with scale invariant
feature transform (SIFT) descriptors. Moreover, if the two
main registration methods have been evaluated (demons
and FFD), other methods should be evaluated, such as the
level-set method [15] or salient-feature-based registration
[38]. Another limitation is related to the considered images.
The obtained results would be different if considering only
contrast-enhanced or only non-contrast-enhanced images,
or CBCT images. Finally, in a dose accumulation purpose,
we only evaluated the impact of DIR, and not in particular
the dose mapping method. In this study, we used the
“classical” trilinear interpolation but other methods, such as
energy/mass mapping [39] have been proposed.
Finally, we did not evaluate in this work the capability of
DIR methods to adequately describe tumor response during
treatment. The account of disappearing tumor is indeed par-
ticularly challenging by usingDIRmethods.Nithiananthan et
al., in a context of CBCT-guided surgical procedures, shown
however, that adaptation of the demons deformable registra-
tion process to include segmentation (i.e., identification of
excised tissue) and an extra dimension in the deformation
field provided a means to accurately accommodate missing
tissue between image acquisitions [40].
To further investigate this issue of the DIR performance
in the presence of tumor variation, Mencarelli et al. used
implanted small gold markers around the tumor, represen-
tative of a part of the tumor border, and in 13 oropharynx
carcinomas [16]. Like in our study, they avoided the ground
truth problem by computing the DIR algorithm performance
with a measure relative to two observers. Otherwise, even
by reducing the interobserver variability, the performance of
their method was comparable to our best method with an
accuracy and a precision of 2.2mm and of 0.59mm, respec-
tively. However, they did not measure the impact of their
DIR method performance in term of dose accumulation,
especially in the high gradient zone. The conclusion of this
recent study was that the B-spline-based DIR method was
not capable of capturing the displacement of tumor borders,
and that precision degraded during the course of treatment.
Consequently, the use of DIR for specifically tumor dose
accumulation in HNC cannot be applied for ART.
5. Conclusion
In this study, we evaluated 10 DIR strategies for dose accu-
mulation in the context of IMRT for locally advanced HNC.
We showed that the choice of the metric or of the image
preprocessing was at least as important as the registration
method. The best results were obtained by demons’ and FFD
methods, with both MI and filtered CTs. We showed that, if
the estimated local accumulated dose has to be considered
carefully, the most accurate methods provide the means to
detect over- or underirradiation for healthy tissues.
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